The Rate of Adverse Events Related to Hypnosis During Clinical Trials

被引:14
|
作者
Bollinger, Jared W. [1 ]
机构
[1] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA
关键词
adverse events; clinical trials; hypnosis; hypnotherapy; patient safety; RANDOMIZED CONTROLLED-TRIALS; STAGE HYPNOSIS; METAANALYSIS; EFFICACY; SEQUELAE; SAFETY; RISKS;
D O I
10.1080/00029157.2017.1315927
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
The rate of adverse events associated with medical and psychological interventions is important to regulators who oversee clinical research. There have been relatively few reports on the frequency of adverse events associated with hypnosis. The current article collected data from a publically available register (ClinicalTrials.gov) on adverse events reported during clinical trials that used hypnosis. The rate of serious adverse events likely attributable to hypnosis was 0%. The rate of other adverse events was 0.47%. This rate was similar to previous reports. However, several trials in the register that used hypnosis did not report adverse event data. For the trials that did report adverse events, there was substantial variability in reporting. Another limitation was the lack of generalizability as all studies included in the analysis used hypnosis to treat side-effects related to medical conditions or procedures as opposed to psychiatric conditions. Future clinical trials using hypnosis should use more precise assessment methods to report adverse events, especially when tested in samples with mental health disorders.
引用
收藏
页码:357 / 366
页数:10
相关论文
共 50 条
  • [1] Clinical trials on adverse events of therapy
    Alonso, Miguel Araujo
    [J]. MEDWAVE, 2011, 11 (09):
  • [2] Adverse events during antipsychotic clinical trials of elderly patients with dementia
    Kryzhanovskaya, L
    Cavazzoni, P
    Young, C
    Polzer, J
    Jansen, J
    Baker, R
    [J]. SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 565 - 566
  • [3] Serious adverse events in healthy volunteers identified during clinical trials
    Coimbra Hurtado, Jimena
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 : 48 - 48
  • [4] Opioid related adverse events in clinical trials- indicators for abuse liability
    Levy-Cooperman, N.
    Schoedel, K.
    [J]. JOURNAL OF PAIN, 2013, 14 (04): : S5 - S5
  • [6] Conjunctivitis adverse events in dupilumab clinical trials
    Rizova, E.
    Ardeleanu, M.
    Chen, Z.
    Plaum, S.
    Rossi, A.
    Kaur, M.
    Akinlade, B.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 84 - 85
  • [7] Conjunctivitis adverse events in dupilumab clinical trials
    Zirwas, Matthew
    Chovatiya, Raj
    Gold, Linda Stein
    Shumel, Brad
    Praestgaard, Amy
    Chen, Zhen
    Gonzalez, Tayler
    Gherardi, Guy
    Lawless, Emma
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II58 - II59
  • [8] Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials
    Lebwohl, Mark G.
    Papp, Kim A.
    Marangell, Lauren B.
    Koo, John
    Blauvelt, Andrew
    Gooderham, Melinda
    Wu, Jashin J.
    Rastogi, Shipra
    Harris, Susan
    Pillai, Radhakrishnan
    Israel, Robert J.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 78 (01) : 81 - +
  • [9] Seizures as treatment-emergent adverse events during glioblastoma clinical trials.
    Dillman, Robert O.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Assessing adverse events in clinical trials during the era of the COVID-19 pandemic
    Buchanan, James
    Li, Mengchun
    Hendrickson, Barbara
    Bhargava, Parul
    Roychoudhury, Satrajit
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2023, 33 (04) : 466 - 475